Moreover, these data support the hypothesis of targeting DNA-PKcs in poor-risk CLL and demonstrate a validation for the use of a DNA-PK inhibitor [41]. The gene discussed is PRKDC; the disease is B-cell chronic lymphocytic leukemia.